|
|
|
Ignacio Aranguren T.
Ignacio Aranguren T. is Executive Director of Arancia Industrial SA de CV, a company in Guadalajara, Mexico with operations in enzymes, textile rental services, and transportation. He has worked in finance, strategy, corn supply, and plant management for oils and surfactants. An Electrical Engineer from the University of Notre Dame, Mr. Aranguren worked for Hewlett-Packard and obtained an M.B.A. from Stanford before joining Arancia.
Back
to top ^ |
|
|
Charles J. Arntzen, Ph.D.
Dr.
Arntzen is internationally recognized for his work on the development
of transgenic plants to yield oral vaccines to meet the needs of
developing nations where infectious diseases are a major cause of
infant mortality. Professor Arntzen holds the Florence Nelson Presidential
Endowed Chair at Arizona State University in Tempe, and was the
Founding Director of the Arizona Biodesign Institute. He has served
as Chairman of the NIH Biotechnology Policy Board and as Chair of
the Biobased Industrial Products Committee for NAS. He is a member
of the National Academy of Sciences and serves on President Bush's
Council of Advisors on Science & Technology. He also serves
as President/CEO Emeritus of the Boyce Thompson Institute for Plant
Research, Inc., a not-for-profit corporation affiliated with Cornell
University. Dr. Arntzen was elected to the U.S. National Academy
of Sciences in 1983, and to the National Academy of India in 1984
in recognition of his collaborative international research in that
country. In 1984 he joined the DuPont Company in Wilmington, Delaware,
and later became the company's Director of Biotechnology in the
Agricultural Products Department. In 1988 he was appointed Dean
and Deputy Chancellor for Agriculture of Texas A&M University,
and subsequently served as Director of the university's Plant Biotechnology
Program of the Institute of Biosciences and Technology. Dr. Arntzen
has played a major role in many national and international scientific
activities, including service for eight years on the editorial board
of SCIENCE. Dr. Arntzen served until 1998 on the Board of Directors
of DeKalb Genetics, Inc. and is on the Board of Directors of Third
Wave Agbio, Inc.; on the Advisory Board of the Burrill and Company's
Agbio Capital Fund and The Nutraceuticals Fund; and on scientific
advisory boards for Sumitomo Chemical Company, Ltd., Phytera, Inc.,
and Valigen, Inc. He also serves as a Distinguished Advisor on the
Council for Biotechnology.
Back
to top ^ |
|
|
 |
Jim Carruthers, Jr.
Private investor representing Eastbourne Capital Management, L.L.C.
Back
to top ^ |
| |
 |
John K. Giannuzzi
Managing
General Partner, Sherbrooke Capital. |
|
|
|
William F. Kirk ,
Chairman
William
F. Kirk has 37 years of experience in the Agricultural Division
of the DuPont Co., where as Group Vice President he led their $4.5
billion Agriculture Business and served as a member of
the CEO's Strategy/Operating Committee.
Back
to top ^ |
|
|
|
David
J. Kyle, Ph.D.
David
J. Kyle is Founder, President and CEO of Advanced BioNutrition Corp.
Prior to establishing ABN, Dr. Kyle co-founded Martek Biosciences
Corporation (Nasdaq: MATK).
Back
to top ^ |
|
|
|
Walter Locher
Walter Locher is a Principal of the private equity fund managed by SAM
Equity Partners, an entity of SAM Sustainable Asset Management of Zurich,
Switzerland. Prior to joining SAM he held various senior management
positions with the Swiss-based Volkart Group, with assignments in Europe,
Latin America, Asia and the USA. Walter is on the boards of several
companies in North America and Australia.
Back
to top ^ |
|
|
|
Josef R. Wuensch, Ph.D.
Dr. Josef R. Wuensch joined BASF Venture Capital GmbH as CTO in July 2006. Before that from 2004 to 2006 he was Senior Manager Strategic Planning with BASF AG, responsible for Global Innovation Management. Dr. Wuensch started his career in 1992, holding different positions within BASF Group since that time. Dr. Wuensch studied chemistry at the University of Goettingen, obtaining his Ph.D. there in 1992.
Back
to top ^ |
| |
|
Andreas Merkl
Mr. Merkl is Chairman of Sea Change Management, LLC and Executive Director of the Conservation and Community Investment Forum (CCIF). For the past 15 years, he has focused on helping institutional and private investors find and realize environmentally transformative investment opportunities.
As a founding member of McKinsey & Company's Environmental Practice, he specialized in the commercialization and marketing of environmental technologies. He also worked extensively with the firm’s corporate finance practice, focusing especially on entrepreneurial finance issues. In recent years, Mr. Merkl has worked as an adjunct consultant to McKinsey.
Since leaving McKinsey, Mr. Merkl founded CCIF, a San Francisco-based group of investment and business professionals dedicated to applying the tools, strategies and capital sources of the private sector to the challenges of biodiversity conservation. CCIF has worked with many of the leading foundations and multilateral organizations in structuring investment vehicles such as conservation endowments and program-related investment funds. On behalf of its clients, CCIF has also performed due diligence on an extensive array of environment-related investment opportunities.
Mr. Merkl was also Vice President and co-founder of the CH2M HILL Strategy Group, a leading provider of environmental management consulting services worldwide. Most of his work concerned capital planning and the management of complex environmental risks.
Mr. Merkl holds an MBA with distinction from Harvard University, a Master of Regional Planning and Natural Resource Analysis form the University of California at Berkeley and a Bachelor of Arts in Environmental Studies from the University of California at Santa Cruz.
Back
to top ^
|
|
